This interview with an EU-based KOL provides insights into current prescribing habits for COVID-19 prevention, key marketed brands and their placement in the prevention algorithm, and expectations for late-phase pipeline therapies. Key assets highlighted include Comirnaty, Spikevax, Vaxzevria, Nuvaxovid, Evusheld, sipavibart, Pemgarda, Paxlovid, mRNA-1083, PF-07926307 and Novavax’s COVID-Influenza Combination Vaccine. 

This interview was conducted on Oct. 2, 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.